Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report-Reference-Cited by-同舟云学术

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report

Published:2020-03-24 Issue:6 Volume:11 Page:1695-1698
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Wu Xueqian¹,Wang Weiya²,Zou Bingwen¹,Li Yanying¹,Yang Xiaojuan¹,Liu Ning¹,Ma Qizhi¹,Zhang Xiaoxuan³^ORCID,Wang Yongsheng¹⁴^ORCID,Li Dan⁵^ORCID

Affiliation:

1. Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan University and Collaborative Innovation Center Chengdu China

2. Department of Pathology, West China Hospital Sichuan University Chengdu China

3. Department of Oncology The Second Affiliated Hospital of Chongqing Medical University Chongqing China

4. Institute of Drug Clinical Trial, West China Hospital Sichuan University Chengdu China

5. Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital Sichuan University Chengdu China

Funder

National Science and Technology Major Project

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13389

Reference12 articles.

1. Non-small cell lung cancer: current treatment and future advances

2. Genomic alterations in lung adenocarcinoma

3. ALK- rearrangement in non-small-cell lung cancer (NSCLC)

4. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

5. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review;Discover Oncology;2024-02-20

2. Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report;Discover Oncology;2023-04-13

3. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer;Current Oncology;2022-10-16

4. Chimeric RNAs Discovered by RNA Sequencing and Their Roles in Cancer and Rare Genetic Diseases;Genes;2022-04-22

5. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively;Diagnostic Pathology;2022-02-10